KEYNOTE B61 Extended Follow Up of Lenvatinib plus Pembrolizumab in nccRCC 1L

Opinion
Video

An expert discusses key data points from the KEYNOTE B61 extended follow up of Lenvatinib plus pembrolizumab in first line setting in non-clear cell renal cell carcinoma.

Related Videos
Video 3 - "Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial"
Video 2 - "FRESCO-2 Study Design Overview"
Video 5 - "Second-Line Treatment Considerations and Improving Outcomes in Breast Cancer"
Video 4 - "Impressions on Safety Data from EMERALD Subgroup Analysis"
Video 3 - "EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer"
Video 2 - "Importance of Biomarker Testing in Breast Cancer"
Video 1 - "Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases"
Video 4 - "Updates on the iNTEGRATE and ROCKstar Trials"
Video 3 - "Lessons Learned from REACH-3 Clinical Trial"
Video 4 - "Moderate cGvHD with Skin, Eye, and Oral Involvement"